Ornithine Transcarbamylase Deficiency Treatment Market, Global Outlook and Forecast 2022-2028

July 2024 | 60 pages | ID: O5BD24306CF9EN
Market Monitor Global

Abstracts

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder arising due to inadequate levels of OTC, an enzyme that helps decompose and eliminate unwanted nitrogen from the human body. This process is also known as the urea cycle. Deficiency of this enzyme causes excessive nitrogen accumulation, or hyperammonemia, in the blood. Another perilous effect of this genetic disorder is the secretion of elevated levels of ammonia, which is a notorious neurotoxin. Once it reaches the central nervous system, it induces symptoms such as anorexia and overall lethargy.

This report contains market size and forecasts of Ornithine Transcarbamylase Deficiency Treatment in Global, including the following market information:

Global Ornithine Transcarbamylase Deficiency Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Ornithine Transcarbamylase Deficiency Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ornithine Transcarbamylase Deficiency Treatment include Abbott Laboratories, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics, Nestle, Bausch Health Companies, Ultragenyx Pharmaceutical, Arcturus Therapeutics and Acer Therapeutics. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ornithine Transcarbamylase Deficiency Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Type, 2021 (%)

• Oral
• Intravenous

Global Ornithine Transcarbamylase Deficiency Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Ornithine Transcarbamylase Deficiency Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Ornithine Transcarbamylase Deficiency Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Ornithine Transcarbamylase Deficiency Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Abbott Laboratories
• Nutricia (Danone Group)
• Mead Johnson (Reckitt Benckiser)
• Horizon Therapeutics
• Nestle
• Bausch Health Companies
• Ultragenyx Pharmaceutical
• Arcturus Therapeutics
• Acer Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Ornithine Transcarbamylase Deficiency Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Ornithine Transcarbamylase Deficiency Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ORNITHINE TRANSCARBAMYLASE DEFICIENCY TREATMENT OVERALL MARKET SIZE

2.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Size: 2021 VS 2028
2.2 Global Ornithine Transcarbamylase Deficiency Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Ornithine Transcarbamylase Deficiency Treatment Players in Global Market
3.2 Top Global Ornithine Transcarbamylase Deficiency Treatment Companies Ranked by Revenue
3.3 Global Ornithine Transcarbamylase Deficiency Treatment Revenue by Companies
3.4 Top 3 and Top 5 Ornithine Transcarbamylase Deficiency Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Ornithine Transcarbamylase Deficiency Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Ornithine Transcarbamylase Deficiency Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Ornithine Transcarbamylase Deficiency Treatment Market Size Markets, 2021 & 2028
  4.1.2 Oral
  4.1.3 Intravenous
4.2 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts
  4.2.1 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts
  5.2.1 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Market Size, 2021 & 2028
6.2 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue & Forecasts
  6.2.1 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028
  6.3.2 US Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.3.3 Canada Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.3.4 Mexico Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028
  6.4.2 Germany Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.3 France Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.4 U.K. Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.5 Italy Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.6 Russia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.4.8 Benelux Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028
  6.5.2 China Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.5.3 Japan Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.5.4 South Korea Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.5.6 India Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028
  6.6.2 Brazil Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.6.3 Argentina Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028
  6.7.2 Turkey Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.7.3 Israel Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028
  6.7.5 UAE Ornithine Transcarbamylase Deficiency Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott Laboratories
  7.1.1 Abbott Laboratories Corporate Summary
  7.1.2 Abbott Laboratories Business Overview
  7.1.3 Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.1.4 Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.1.5 Abbott Laboratories Key News
7.2 Nutricia (Danone Group)
  7.2.1 Nutricia (Danone Group) Corporate Summary
  7.2.2 Nutricia (Danone Group) Business Overview
  7.2.3 Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.2.4 Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.2.5 Nutricia (Danone Group) Key News
7.3 Mead Johnson (Reckitt Benckiser)
  7.3.1 Mead Johnson (Reckitt Benckiser) Corporate Summary
  7.3.2 Mead Johnson (Reckitt Benckiser) Business Overview
  7.3.3 Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.3.4 Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.3.5 Mead Johnson (Reckitt Benckiser) Key News
7.4 Horizon Therapeutics
  7.4.1 Horizon Therapeutics Corporate Summary
  7.4.2 Horizon Therapeutics Business Overview
  7.4.3 Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.4.4 Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.4.5 Horizon Therapeutics Key News
7.5 Nestle
  7.5.1 Nestle Corporate Summary
  7.5.2 Nestle Business Overview
  7.5.3 Nestle Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.5.4 Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.5.5 Nestle Key News
7.6 Bausch Health Companies
  7.6.1 Bausch Health Companies Corporate Summary
  7.6.2 Bausch Health Companies Business Overview
  7.6.3 Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.6.4 Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.6.5 Bausch Health Companies Key News
7.7 Ultragenyx Pharmaceutical
  7.7.1 Ultragenyx Pharmaceutical Corporate Summary
  7.7.2 Ultragenyx Pharmaceutical Business Overview
  7.7.3 Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.7.4 Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.7.5 Ultragenyx Pharmaceutical Key News
7.8 Arcturus Therapeutics
  7.8.1 Arcturus Therapeutics Corporate Summary
  7.8.2 Arcturus Therapeutics Business Overview
  7.8.3 Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.8.4 Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.8.5 Arcturus Therapeutics Key News
7.9 Acer Therapeutics
  7.9.1 Acer Therapeutics Corporate Summary
  7.9.2 Acer Therapeutics Business Overview
  7.9.3 Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Major Product Offerings
  7.9.4 Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue in Global Market (2017-2022)
  7.9.5 Acer Therapeutics Key News

8 CONCLUSION


9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Ornithine Transcarbamylase Deficiency Treatment Market Opportunities & Trends in Global Market
Table 2. Ornithine Transcarbamylase Deficiency Treatment Market Drivers in Global Market
Table 3. Ornithine Transcarbamylase Deficiency Treatment Market Restraints in Global Market
Table 4. Key Players of Ornithine Transcarbamylase Deficiency Treatment in Global Market
Table 5. Top Ornithine Transcarbamylase Deficiency Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Ornithine Transcarbamylase Deficiency Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Ornithine Transcarbamylase Deficiency Treatment Product Type
Table 9. List of Global Tier 1 Ornithine Transcarbamylase Deficiency Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ornithine Transcarbamylase Deficiency Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Ornithine Transcarbamylase Deficiency Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 32. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Nutricia (Danone Group) Corporate Summary
Table 34. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 35. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Mead Johnson (Reckitt Benckiser) Corporate Summary
Table 37. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 38. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Horizon Therapeutics Corporate Summary
Table 40. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 41. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Nestle Corporate Summary
Table 43. Nestle Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 44. Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Bausch Health Companies Corporate Summary
Table 46. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 47. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Ultragenyx Pharmaceutical Corporate Summary
Table 49. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 50. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Arcturus Therapeutics Corporate Summary
Table 52. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 53. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Acer Therapeutics Corporate Summary
Table 55. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product Offerings
Table 56. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Ornithine Transcarbamylase Deficiency Treatment Segment by Type in 2021
Figure 2. Ornithine Transcarbamylase Deficiency Treatment Segment by Application in 2021
Figure 3. Global Ornithine Transcarbamylase Deficiency Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Ornithine Transcarbamylase Deficiency Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Ornithine Transcarbamylase Deficiency Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Ornithine Transcarbamylase Deficiency Treatment Revenue in 2021
Figure 8. By Type - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 12. US Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 24. China Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Ornithine Transcarbamylase Deficiency Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Nestle Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)